Scarica l'app Stockscreener
1.57
0.64%
0.01
Dopo l'orario di chiusura:
1.60
0.03
+1.91%
Precedente Chiudi:
$1.56
Aprire:
$1.61
Volume 24 ore:
47,091
Relative Volume:
0.32
Capitalizzazione di mercato:
$22.43M
Reddito:
-
Utile/perdita netta:
$-30.16M
Rapporto P/E:
-4.6176
EPS:
-0.34
Flusso di cassa netto:
$-39.49M
1 W Prestazione:
-5.99%
1M Prestazione:
-6.55%
6M Prestazione:
-26.98%
1 anno Prestazione:
-48.52%
Intervallo 1D:
$1.56
$1.61
Intervallo di 1 settimana:
$1.56
$1.7046
Portata 52W:
$1.56
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
Nome
Dare Bioscience Inc
Settore
Industria
Telefono
858-926-7655
Indirizzo
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
1.57 | 22.29M | 0 | -30.16M | -39.49M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dare Bioscience Inc Borsa (DARE) Ultime notizie
Daré Bioscience Updates Investor Presentation Under Regulation FD - TipRanks
Daré Bioscience (NASDAQ: DARE) updates investor presentation and furnishes 8-K - Stock Titan
DARE Should I Buy - Intellectia AI
DARE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Daré Bioscience gets FDA clearance for HPV treatment trial By Investing.com - Investing.com India
Daré Bioscience gets FDA clearance for HPV treatment trial - Investing.com Australia
Dare Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - Bitget
Daré Bioscience Announces FDA Clearance of IND for Phase 2 - GlobeNewswire
New vaginal insert targets virus behind nearly all cervical cancers - Stock Titan
Dare Bioscience (DARE) CEO subscribes to Reg A units with warrants - Stock Titan
DARE SEC FilingsDare Bioscience Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Dare Bioscience Launches Telehealth Consultations for Women's Arousal Cream - Intellectia AI
Dare Bioscience (DARE) Launches Telehealth for Topical Sildenafi - GuruFocus
First-of-its-kind arousal cream for women offers US-wide telehealth access - Stock Titan
Dare Bioscience Secures Strategic Autonomy with Key Asset Reversion - AD HOC NEWS
Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st
Dare Bioscience launches preferred stock and warrant offering on Nasdaq - Investing.com
Daré Bioscience Launches Regulation A Preferred Unit Offering - TipRanks
Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In Growth - Yahoo Finance
Dare Bioscience (NASDAQ:DARE) Share Price Passes Below 50-Day Moving Average – What’s Next? - Defense World
Daré Bioscience issues updated investor corporate presentation - MSN
Daré Bioscience Issues Updated Investor Corporate Presentation - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call Transcript - MSN
Daré targets DARE to PLAY launch in December 2025 as dual path strategy accelerates - MSN
Dare Bioscience secures additional NIAID funding for HPV treatment - MSN
Dare Bioscience Earnings Notes - Trefis
Is Dare Bioscience Inc (DARE) a opportunity to investors? - uspostnews.com
Viagra for women rolling out in select states - NewsNation
A History of Outperforming Analyst Forecasts and Beating the Odds: Dare Bioscience Inc (DARE) - setenews.com
‘Viagra’ for women hits the shelves – 30 years after men got little blue pills - AOL.com
Sildenafil cream for female sexual arousal disorder available to prescribe in select states - Urology Times
DARE to PLAY sildenafil cream becomes commercially available for women in select states - Contemporary OB/GYN
Dare Bioscience (DARE) Launches Prescription for Women's Topical Arousal Cream - GuruFocus
Daré Bioscience Launches First-Ever Sildenafil Cream for Women, DARE to PLAY™ Sildenafil Cream, Enhancing Female Arousal and Sexual Health - Quiver Quantitative
Daré Bioscience (NASDAQ: DARE) starts 503B DARE to PLAY cream access in select states - Stock Titan
Viagra goes pink (finally!): First-of-its-kind cream promises to jump-start arousal in women - New York Post
Dare Bioscience stock maintains Buy rating at H.C. Wainwright as Bayer exits - Investing.com Canada
DARE: HC Wainwright & Co. Reiterates 'Buy' Rating with $12 Targe - GuruFocus
Daré Bioscience to regain rights to hormone-free contraceptive from Bayer By Investing.com - Investing.com Canada
Dare Bioscience (DARE) Regains Ovaprene Rights from Bayer - GuruFocus
Daré Bioscience to regain rights to hormone-free contraceptive from Bayer - Investing.com
Dare Bioscience announces return of rights to Ovaprene phase 3 program ongoing positive interim data - marketscreener.com
Dare Bioscience Announces Return Of Rights To Ovaprene Phase 3 Program Ongoing Positive Interim Data - TradingView — Track All Markets
Daré Bioscience (NASDAQ: DARE) regains Ovaprene rights after Phase 3 interim data - Stock Titan
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization - Sahm
H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
[1-A] Dare Bioscience, Inc. SEC Filing - Stock Titan
Daré Bioscience receives $3.6 million grant payment for contraceptive work By Investing.com - Investing.com Nigeria
DARE Secures Additional $3.6 Million from Gates Foundation - GuruFocus
Daré Bioscience Receives $3.6 Million in Additional Grant Funding - The Manila Times
Daré Bioscience receives $3.6 million grant payment for contraceptive work - Investing.com
Dare Bioscience Inc Azioni (DARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):